MYL9 and neoplasm: The promoter methylation of CXCL12 was acted as a prognostic biomarker in prostate cancer patients25 or sporadic breast cancer.26 The low expression level of MYL9 is correlated with a significantly reduced median survival rate in colon cancer patients and might act as clinical biomarkers for the early diagnosis of colon cancer.27 MMP9 and MMP11, both of which belong to Proteins of the matrix metalloproteinase (MMP) family, were reported as tumor biomarkers28 or associated with tumor survival,29 and targeted by an inhibitor marimastat.